^
    Back
    Association details:
    Biomarker:HR positive
    Cancer:HER2 Negative Breast Cancer
    Drug:SY-5609 (CDK7 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors

    Excerpt:
    ...Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer....
    Trial ID:
    NCT04247126
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2023
    Title:

    Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC).

    Published date:
    05/25/2023
    Excerpt:
    SY-5609 + fulvestrant has an acceptable safety profile consistent with SA SY-5609 or fulvestrant. The mechanistic rationale for CDK7 inhibition in HR+, HER2- BC and the tolerability and encouraging early activity in this heavily pretreated population support future investigation of SY-5609 in combination with SERDs.
    Secondary therapy:
    fulvestrant
    DOI:
    10.1200/JCO.2023.41.16_suppl.3081
    Trial ID:
    NCT04247126